FDA approves weight-management drug Saxenda
The U.S. Food and Drug Administration today approved Saxenda (liraglutide [rDNA origin] injection) as a treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity. (Source: Food and Drug Administration)
Source: Food and Drug Administration - December 23, 2014 Category: American Health Source Type: news
Genotropin (Somatropin [rDNA origin]) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 27, 2014 Category: Drugs & Pharmacology Source Type: news
Stada secures third license for copycat biotech drug: CEO
BAD VILBEL Germany (Reuters) - Germany's Stada plans to bring a copy of Eli Lilly's Forteo osteoporosis treatment to market, its chief executive said, as the generic drugmaker moves further into the sale of cheaper alternatives for costly biotech drugs. (Source: Reuters: Health)
Source: Reuters: Health - October 10, 2014 Category: Consumer Health News Tags: healthNews Source Type: news
Denosumab After Teriparatide Boosts Bone-Density Gains Denosumab After Teriparatide Boosts Bone-Density Gains
Newly reported data should guide clinicians as they make initial osteoporosis-treatment decisions, researchers say. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 19, 2014 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Review Examines Efficacy and Safety of Osteoporosis Drugs (FREE)
By Amy Orciari Herman
Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD
Bisphosphonates, denosumab, teriparatide, and raloxifene all reduce risk for fracture relative to placebo in women with osteoporosis, according to a federally commissioned systematic review … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 9, 2014 Category: Primary Care Source Type: news
Gattex (Teduglutide [rDNA origin] for Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 10, 2014 Category: Drugs & Pharmacology Source Type: news
Basal insulin Toujeo® New Drug Application accepted
The U.S. Food and Drug Administration has accepted for review a New Drug Application for Toujeo® (insulin glargine [rDNA origin] injection, 300 U/ml), an investigational basal insulin. (Source: Pharmacy Europe)
Source: Pharmacy Europe - July 8, 2014 Category: Drugs & Pharmacology Authors: AMcculloch Tags: *** Editor's Pick Diabetes investigational basal insulin Latest News sanofi Toujeo Source Type: news
Critical Pharma Begins Phase 1 Trial Of Nano-Enabled Osteoporosis Drug
Critical Pharmaceuticals with collaborators The University of Nottingham and Nottingham University Hospitals NHS Trust announced the initiation of the first Phase I trial for a nano-enabled intranasal teriparatide product. The product will be evaluated for the treatment of osteoporosis in post-menopausal women. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - April 16, 2014 Category: Pharmaceuticals Source Type: news
Critical Pharma announces start of first Phase I study of nano-enabled intranasal teriparatide
UK-based biotechnology firm Critical Pharmaceuticals has announced the start of the first Phase I clinical trial of a nano-enabled intranasal teriparatide product in healthy post-menopausal women for the treatment of osteoporosis. (Source: Drug Development Technology)
Source: Drug Development Technology - April 15, 2014 Category: Pharmaceuticals Source Type: news
Combo Therapy Sustains Bone-Density ImprovementsCombo Therapy Sustains Bone-Density Improvements
Two-year results of a combination of denosumab and teriparatide therapy show sustained improvements in bone-mineral density that exceed that expected with either drug alone. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 9, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Apidra (Insulin Glulisine [rDNA origin] Inj) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 23, 2013 Category: Drugs & Pharmacology Source Type: news
Lantus (Insulin Glargine [rDNA origin] Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 17, 2013 Category: Drugs & Pharmacology Source Type: news
Combination Drug Therapy May Be Best Treatment For Osteoporosis
The combination of two different drugs for osteoporosis was found to increase bone mineral density (BMD) more than treatment with either drug alone, according to the results of a small clinical trial published in The Lancet. The combination, which included teriparatide, a bone-building (anabolic) drug, and denosumab, a targeted therapy to stop bone loss, also increased BMD better than previously reported with any available treatment in postmenopausal women with osteoporosis... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 17, 2013 Category: Consumer Health News Tags: Clinical Trials / Drug Trials Source Type: news
Teriparatide-Denosumab Combo Strengthens Postmenopausal BoneTeriparatide-Denosumab Combo Strengthens Postmenopausal Bone
A combination of teriparatide, which builds bone, and denosumab, which reduces bone loss, improved bone density in postmenopausal women compared with either drug alone. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 15, 2013 Category: Consumer Health News Tags: Internal Medicine News Source Type: news
Treatment with 2 osteoporosis drugs better at increasing bone density than single-drug therapy (EurekAlert, 14 May 2013)
A study in The Lancet assesses combination therapy combining denosumab and teriparatide vs either therapy alone in a total of 94 women with postmenopausal osteoporosis. Full article (Source: Society for Endocrinology)
Source: Society for Endocrinology - May 15, 2013 Category: Endocrinology Source Type: news
